Spots Global Cancer Trial Database for I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
Official Title: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
Study ID: NCT00590096
Interventions
Study Description
Brief Summary: I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors
Detailed Description: Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide
Eligibility
Minimum Age: 2 Weeks
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Michael J Gelfand, M.D.
Affiliation: Children's Hospital Medical Center, Cincinnati
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
